TY - JOUR
T1 - Differences in disease presentation, management techniques, treatment outcome, and toxicities in African-American women with early stage breast cancer treated with breast-conserving therapy
AU - Vicini, Frank
AU - Jones, Pamela
AU - Rivers, Aeisha
AU - Wallace, Michelle
AU - Mitchell, Chris
AU - Kestin, Larry
AU - Jaiyesimi, Ishmael
AU - Dekhne, Nayana
AU - Martinez, Alvaro
PY - 2010/7/15
Y1 - 2010/7/15
N2 - BACKGROUND: Data on patients who received breast-conserving therapy (BCT) for early stage breast cancer were examined to detect differences in disease presentation, management techniques, long-term treatment outcomes, and toxicities based on race. METHODS: Six hundred ninety-nine women with breast cancer (39 African-American [AA] women and 660 Caucasian [C] women) who received BCT were analyzed on race, clinical and pathologic characteristics at presentation, management techniques, treatment-related toxicities, recurrence, and survival. The median follow-up was 12.2 years. RESULTS: At diagnosis, AA women were younger (aged <50 years, 49% vs 29%; P = .002), had larger tumors (mean, 17.0 mm vs 13.9 mm; P = .032), had more estrogen receptor-negative tumors (56% vs 18%; P < .001), and higher nuclear grade tumors (grade 3, 52% vs 29%; P = .006). Compared with C women, AA women more frequently received adjuvant chemotherapy (59% vs 19%; P < .001) and lymph node irradiation (26% vs 13%; P = .033). No other significant treatment differences were observed. After treatment, AA women experienced more breast pain (P = .001), more arm edema (P = .046), and less excellent cosmetic results (P = .008), but there were no statistically significant differences in local recurrence (P = .232), distant metastasis (P = .263), overall survival (P = .131), or cause-specific survival (P = .092) based on race. CONCLUSIONS: The current results suggested that AA women present with larger and more aggressive breast tumors and, as a result, more frequently received adjuvant chemotherapy and lymph node irradiation. Small differences in treatment-related toxicities and cosmesis were observed, but no differences in efficacy were identified.
AB - BACKGROUND: Data on patients who received breast-conserving therapy (BCT) for early stage breast cancer were examined to detect differences in disease presentation, management techniques, long-term treatment outcomes, and toxicities based on race. METHODS: Six hundred ninety-nine women with breast cancer (39 African-American [AA] women and 660 Caucasian [C] women) who received BCT were analyzed on race, clinical and pathologic characteristics at presentation, management techniques, treatment-related toxicities, recurrence, and survival. The median follow-up was 12.2 years. RESULTS: At diagnosis, AA women were younger (aged <50 years, 49% vs 29%; P = .002), had larger tumors (mean, 17.0 mm vs 13.9 mm; P = .032), had more estrogen receptor-negative tumors (56% vs 18%; P < .001), and higher nuclear grade tumors (grade 3, 52% vs 29%; P = .006). Compared with C women, AA women more frequently received adjuvant chemotherapy (59% vs 19%; P < .001) and lymph node irradiation (26% vs 13%; P = .033). No other significant treatment differences were observed. After treatment, AA women experienced more breast pain (P = .001), more arm edema (P = .046), and less excellent cosmetic results (P = .008), but there were no statistically significant differences in local recurrence (P = .232), distant metastasis (P = .263), overall survival (P = .131), or cause-specific survival (P = .092) based on race. CONCLUSIONS: The current results suggested that AA women present with larger and more aggressive breast tumors and, as a result, more frequently received adjuvant chemotherapy and lymph node irradiation. Small differences in treatment-related toxicities and cosmesis were observed, but no differences in efficacy were identified.
KW - African Americans
KW - Breast cancer
KW - Breast-conserving therapy
KW - Racial disparities
KW - Radiation
UR - http://www.scopus.com/inward/record.url?scp=77954916649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954916649&partnerID=8YFLogxK
U2 - 10.1002/cncr.25088
DO - 10.1002/cncr.25088
M3 - Article
C2 - 20564071
AN - SCOPUS:77954916649
SN - 0008-543X
VL - 116
SP - 3485
EP - 3492
JO - Cancer
JF - Cancer
IS - 14
ER -